Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Better survival predictions for liver cancer patients are here. Researchers developed two novel prognostic indexes — mMDN/ALBI and mUS/ALBI — that combine liver function and tumor burden to more accurately predict overall survival in patients with Barcelona Clinic Liver Cancer Stage B (BCLC-B) hepatocellular carcinoma (HCC). The new indexes outperformed conventional scoring tools like the ALBI and Tokyo scores in a study of nearly 1,900 patients.
Better survival predictions for liver cancer patients are here
Researchers have developed two novel prognostic indexes — mMDN/ALBI and mUS/ALBI — designed specifically for patients with Barcelona Clinic Liver Cancer Stage B (BCLC-B) hepatocellular carcinoma (HCC). Published in The Oncologist, the study found these new tools outperform conventional scoring systems by combining two critical factors: functional hepatic reserve (measured via the albumin-bilirubin, or ALBI, score) and tumor burden (based on maximum tumor diameter and number of nodules).
The retrospective study enrolled 1,843 patients across four hospitals. The indexes were built by dividing modified tumor burden scores (mMDN or mUS) by the absolute ALBI value, yielding a single composite number that better stratifies patient prognosis. Crucially, the tools rely on objective, widely available clinical data — making them broadly applicable across healthcare settings.
Key Takeaways
Why it matters: Accurate prognosis in BCLC-B HCC is essential for guiding treatment decisions. These new indexes give clinicians a more precise, stage-specific tool to estimate survival and tailor care accordingly.